These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide. Kim SY; Benowitz NL Drug Saf; 1990; 5(6):393-420. PubMed ID: 2285495 [TBL] [Abstract][Full Text] [Related]
25. Current status of cardiac glycoside drug interactions. Hooymans PM; Merkus FW Clin Pharm; 1985; 4(4):404-13. PubMed ID: 2412751 [TBL] [Abstract][Full Text] [Related]
26. Population pharmacokinetics of quinidine. Fattinger K; Vozeh S; Ha HR; Borner M; Follath F Br J Clin Pharmacol; 1991 Mar; 31(3):279-86. PubMed ID: 2054269 [TBL] [Abstract][Full Text] [Related]
27. Physiologic pharmacokinetic modeling of gastrointestinal blood flow as a rate-limiting step in the oral absorption of digoxin: implications for patients with congestive heart failure receiving epoprostenol. Carlton LD; Pollack GM; Brouwer KL J Pharm Sci; 1996 May; 85(5):473-7. PubMed ID: 8742937 [TBL] [Abstract][Full Text] [Related]
28. Principles of drug administration in renal insufficiency. Lam YW; Banerji S; Hatfield C; Talbert RL Clin Pharmacokinet; 1997 Jan; 32(1):30-57. PubMed ID: 9012555 [TBL] [Abstract][Full Text] [Related]
29. Pitfalls of pharmacokinetic dosage guidelines in renal insufficiency. Turnheim K Eur J Clin Pharmacol; 1991; 40(1):87-93. PubMed ID: 2060552 [TBL] [Abstract][Full Text] [Related]
30. Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs. Yuan R; Venitz J Int J Clin Pharmacol Ther; 2000 May; 38(5):245-53. PubMed ID: 10839468 [TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies. Pentel P; Benowitz N Clin Pharmacokinet; 1984; 9(4):273-308. PubMed ID: 6380870 [TBL] [Abstract][Full Text] [Related]
32. Clinical relevance of the effect of hepatic disease on drug disposition. Bond WS Am J Hosp Pharm; 1978 Apr; 35(4):406-14. PubMed ID: 645712 [TBL] [Abstract][Full Text] [Related]
33. Decreased renal clearance of digoxin in chronic congestive heart failure. Naafs MA; van der Hoek C; van Duin S; Koorevaar G; Schopman W; Silberbusch J Eur J Clin Pharmacol; 1985; 28(3):249-52. PubMed ID: 4007028 [TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. Duchin KL; McKinstry DN; Cohen AI; Migdalof BH Clin Pharmacokinet; 1988 Apr; 14(4):241-59. PubMed ID: 3292102 [TBL] [Abstract][Full Text] [Related]
35. Drug interactions involving cimetidine--mechanisms, documentation, implications. Greene W Q Rev Drug Metab Drug Interact; 1984; 5(1):25-51. PubMed ID: 6152350 [TBL] [Abstract][Full Text] [Related]
37. Effect of acute and chronic exercise on hepatic drug metabolism. Døssing M Clin Pharmacokinet; 1985; 10(5):426-31. PubMed ID: 3899456 [TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetics of procainamide from routine clinical data. Grasela TH; Sheiner LB Clin Pharmacokinet; 1984; 9(6):545-54. PubMed ID: 6509861 [TBL] [Abstract][Full Text] [Related]
39. Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity. Matzke GR; Frye RF Drug Saf; 1997 Mar; 16(3):205-31. PubMed ID: 9098657 [TBL] [Abstract][Full Text] [Related]
40. Digoxin-quinidine interaction Pharmacokinetic evaluation. Hager WD; Fenster P; Mayersohn M; Perrier D; Graves P; Marcus FI; Goldman S N Engl J Med; 1979 May; 300(22):1238-41. PubMed ID: 431681 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]